|
Catherine Dargan is co-chair of our mergers & acquisitions practice group. She has broad experience in mergers and acquisitions, both public and private, and strategic partnering arrangements. In addition to structuring and negotiating transactions, she assists clients with corporate governance issues, compliance matters, financing agreements, employment and consulting arrangements, and other matters. Ms. Dargan also regularly advises clients on a variety of commercial agreements relating to manufacturing, supply, and distribution of core products.
She represents clients in a variety of industries including life sciences, consumer products, technology, government contractors, communications and media; sports and entertainment; pharmaceutical, equipment, and food product manufacturing; and consulting and advisory services.
Representative Matters
- Represented Boehringer Ingelheim in its acquisition of certain animal health products divested in connection with the Pfizer-Wyeth merger.
- Advised Salix Pharmaceuticals in its $300 million acquisition of Oceana Therapeutics, Inc.
- Represented Abbott Vascular in its acquisition of Evalve, Inc., a medical device developer, for up to $410 million.
- Advised Eli Lilly in its acquisition of SGX Pharmaceuticals, Inc. (NASDAQ: SGXP), a San Diego-based biotechnology company, and in the divestiture of its Tippecanoe manufacturing facility to Evonik Industries.
- The Procter & Gamble Company in its 50/50 joint venture with Inverness Medical Innovations, Inc. for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products in a transaction valued at $650 million.
- Represented Abbott Laboratories in its $3.7 billion acquisition of Kos Pharmaceuticals, Inc. (NASDAQ: KOSP).
Pro Bono
- Represented a non-profit, non-partisan policy organization dedicated to engaging young adults in the political process.
- Advised a non-profit in various consulting and services arrangements.
Memberships and Affiliations
- Faculty Member, Drafting Corporate Agreements — Letters of Intent, Confidentiality and Standstill Agreements, Practicing Law Institute (2011-2012)
|
|